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Abstract: In the last two decades, targeted therapies have enhanced tumor patient care and treatment
success, however, metastatic growth still cannot be stopped efficiently and, therefore, mortality rates
remain high. Prevention strategies against formation of metastases are the most promising approach
we have, however, due to lack of clinical validation studies, they have not yet entered routine
clinical care. In order to smooth the way for efficient prevention, further preclinical and large
clinical studies are required. In this context, the underlying molecular mechanisms and factors that
lead to metastatic growth have to be explored, and potential preventive agents have to be tested.
Thereby, special attention has to be paid to natural bioactive compounds which do not exert major
adverse effects, like the plant-derived polyphenol Curcumin, which is known to be a powerful
antitumor agent. So far, most of the preclinical studies with Curcumin have focused on its effect on
inhibiting tumor cell proliferation and invasion, although, it is known that it also inhibits metastatic
spread in vivo. This review discusses the preventive potential of this natural compound not only
against tumor onset, but also against formation of metastases.
Keywords: curcumin; cancer; metastases; prevention
1. Introduction
The number of tumor cases are continuously rising, and while today there are 14.1 million new
cancer cases registered worldwide, it is expected to be 23.6 million in the year 2030 (International
Agency for Research on Cancer: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx; accessed on
May 2018). At present, 8.2 million persons die due to metastases from malignant tumors. In most
cases, formation of metastases is an irreversible process accompanied by therapy resistance [1].
At present, tumors in the metastatic setting are treated predominantly with chemotherapy,
which exerts harmful side effects and, in many cases, results in therapy resistance, confronting the
vast majority of patients with a terminal illness that is to a large extent incurable by current
therapeutic regimens.
Therefore, it is more beneficial to prevent cancer and its progression to the metastatic disease
before this process starts. Efficient prevention strategies comprise the use of pharmacological agents
or bioactive substances to impede, arrest, or reverse tumorigenesis at its early stage, which is the
definition for chemoprevention, a term introduced in the early 1990s by Michael Sporn [2]. Since these
days, chemoprevention was successful in many preclinical and clinical studies [3]. The outcome
was that chemopreventive agents—which are natural substances, molecules, or synthetic derivates
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with negligible side effects—can control signal transduction and protein expression and thereby exert
antitumor and antimetastatic potency.
While conventional cancer therapies in terms of synthesized antineoplastic drugs, which can be
targeted (e.g., antibodies) or nontargeted (e.g., most chemotherapeutic agents), are accompanied by
severe side effects and drug resistance, prevention is a strategy that applies predominantly plant-derived
nontoxic natural substances or synthetic molecules with preclinically proven antitumorigenic effects and
low side effects.
The term “prevention” was originally used in health management and was then translated
into cancer patients’ care. Prevention is divided into primary, secondary, and tertiary prevention.
The definitions are:
Primary prevention aims to prevent disease or injury before it ever occurs. It refers to activities or
measures that are directed at reducing the risk of exposure to a risk factor or health determinant.
Secondary prevention aims to reduce the impact of a disease or injury that has already occurred.
This is done by detecting and treating disease or injury as soon as possible to halt or slow its progress.
In terms of cancer this would apply at the stage of tumor initiation in order to prevent progression.
Tertiary prevention aims to soften the impact of an ongoing illness or injury that has lasting effects.
This is done by helping people manage long-term, often-complex health problems in order to improve
their ability to function, their quality of life and their life expectancy (https://www.iwh.on.ca/wrmb/
primary-secondary-and-tertiary-prevention, accessed on 8 June 2018).
Translated into terms of cancer patients’ care, primary prevention encompasses all interventions
that impede the development of the cancerous process and includes, for example, lifestyle counseling
and coaching and product safety. All sets of interventions leading to the discovery and control of
cancerous or precancerous processes, like screening, early detection, and effective treatment, belong to
secondary prevention [4]. The goal of tertiary prevention is to reduce morbidity and disability in
people diagnosed with, and being treated for, cancer. An additional challenge of tertiary prevention is
to increase the overall efficiency of patient treatment through the inclusion of interventions in order to
prevent comorbidities, risk of recurrence, and second cancers.
The polyphenol Curcumin (diferuloylmethane) is extracted from the plant turmeric
(Curcuma longa) and widely used as a spice component. The antioxidant compound is applied in
traditional Indian and Chinese medicine to treat inflammatory disorders [5]. Current preclinical and
clinical studies revealed that Curcumin exerts antiproliferative and proapoptotic effects against various
tumors in vitro [6–8] and in vivo, and that it suppresses carcinogenesis of the breast [9] and other
organs [10–12]. Curcumin is able to suppress cancer cell growth by interfering with the tumor cell
cycle [13] and inhibits tumor cell invasion through regulation of cytokines, growth factors and their
receptors, enzymes, and adhesion molecules [14–19]. Furthermore, Curcumin modulates the activity
of transcription factors and their signaling pathways, as well as oncogenes and tumor suppressor
genes [18,20]. Our group has extensively studied the preventive effect of Curcumin on metastatic
growth in various in vivo models of breast and prostate cancer [14,16] and the underlying molecular
mechanisms [14,15,21]. Because of its potency against tumor progression and formation of metastases
and its negligible side effects, Curcumin is highly suitable for chemoprevention of cancer on all levels
embracing primary, secondary, and tertiary prevention.
By preventing or retarding tumor initiation, progression, metastatic disease, and comorbidities,
people can have high quality of life instead of waiting until the malignancy proceeds and only
antineoplastic therapies with huge side effects have to be applied. The goal of cancer prevention is
to expand the lifespan with high quality of life, where people might then die of another disease of
advanced age.
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2. Chemopreventive Properties of Curcumin
Many preclinical studies in the last 20 years have focused on unraveling the molecular mechanisms
of the antitumorigenic properties of Curcumin in order to evaluate the chemopreventive potential of
this natural bioactive compound [14–16,21–24].
The chemopreventive activities of Curcumin involve a variety of mechanisms playing a role in
tumorigenesis and tumor progression, for example, strong antioxidant effect by direct scavenge of
reactive oxygen species, upregulation of carcinogen-detoxifying enzymes/antioxidants, as well as
activation of programmed cell death (apoptosis), and the inhibition of various transcription factors
with nuclear factor-κB (NFκB). It has been shown by us and others that Curcumin is able to modulate
several signal transcription pathways and mainly acts by inhibiting the activity of NFκB, a transcription
factor associated with inflammatory diseases and tumor progression [13–16,24].
In particular, the inhibition of the NFκB pathway by Curcumin leads to the alteration of various
tumor-associated genes, gene products, and noncoding RNAs (miRNAs). In this context, proinflammatory
cytokines and the mRNA expression of pro-metastatic enzymes, such as matrix metalloproteinases (MMPs)
are inhibited. Similarly, other factors/enzymes, such as cyclooxygenase (COX)-2, are repressed and
several other important cellular effectors are influenced. In consequence, Curcumin has been shown to
interfere with a multitude of tumor-associated processes, including inflammation, cell cycle, apoptosis,
cell survival, proliferation (by growth factor receptor inhibition), invasion, and metastasis [15,16].
We have extensively investigated the NFκB pathway preclinically in cell models of metastatic
breast and prostate cancer. Curcumin prevents NFκB activation by blocking phosphorylation and
degradation of IκBα, the inhibitor of κBα. Thereby, the NFκB subunit p65 does not get phosphorylated
and does not translocate into the nucleus [14,15]. In consequence, tumor-associated genes and
gene products are not expressed (Figure 1). NFκB-regulated gene products that control tumor cell
invasion are, among others, matrix-degrading proteases like matrix metalloproteinases (MMPs) and
urokinase-type plasminogen activator (uPA) or inflammatory cytokines [25]. The inhibitory effect
of Curcumin on NFκB leads to reduced tumor cell proliferation and growth and induced apoptosis.
The concerted action of all these effects prevents tumor cell invasion and metastases, as illustrated in
Figure 2, based on our results on metastatic prostate cancer cells [14]. The inhibition of the transcription
factor NFκB is therefore a major target for prevention of cancer onset and progression.
2.1. Curcumin Induces Apoptosis and Inhibits Proliferation and Cell Growth
The loss of a fully functional apoptotic program of malignant tumor cells is a major target of
chemoprevention of cancer. Apoptosis can be initiated by p53 (intrinsic pathway), as well as through
a variety of extracellular signals (extrinsic pathway). The caspase-3, -8 and -9 are activated upon an
interplay between the extrinsic and the intrinsic apoptotic pathways. In addition, the signaling pathways
of PI3K/Akt (Phosphatidylinositol-3-Kinase and Protein Kinase B), MAPK (Mitogen-Activated Protein
Kinase), and NFκB, which control cell proliferation and survival, are indirectly involved in the
regulation of apoptotic cell death.
Curcumin has been found to suppress carcinogenesis of the breast [26] and other organs [10–12]
in vivo and against diverse tumors in vitro [6–8,27], exerting significant antiproliferative and
proapoptotic effects. Curcumin-induced activation of caspases and release of cytochrome C [28] and
the repression of cell survival factors via the inhibition of the NFκB pathway (see below) are discussed
as molecular mechanisms underlying the strong anticancer effect of Curcumin. The plant-derived
polyphenol activated caspases-3, -7, -8, and -9 in several colon cancer cell lines, but reduced activation
of caspases related to the mitochondrial pathway, together with a partial blocking of apoptosis-inducing
factor (AIF) [29]. Curcumin has been shown to increase the permeability of the mitochondrial
membrane and the collapse of its membrane potential. Further effects of Curcumin include the
inhibition of Akt/protein kinase B (PKB) phosphorylation in breast cancer cells, leading to increased
apoptosis [30].
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Figure 1. Schematic illustration of nuclear factor-κB (NFκB) signaling in the tumor environment.
In resting cells, the NFκB dimer is bound to its inhibitor (IκB) and remains inactive in the
cytoplasm. The activation cascade starts through binding of a ligand (TNFα = tumor necrosis factor α,
TNFαR = TNFα-receptor, GF/CR = growth-factor/chemokine-receptor) to its receptor. Activation via
TNFα occurs mainly through Tak1 (TGFβ-activated kinase 1) and via growth factors and/or cytokines,
mainly through Akt (v-akt murine thymoma viral oncogene homolog). This leads to activation of
the IKK complex (inhibitor of κB kinases; IKKα, β, γ). By activating the IKK-complex, the inhibitor
of κB (IκB) is phosphorylated and the NFκB dimer is released and phosphorylated, which leads to
translocation into the nucleus, where NFκB binds to the respective DNA promotor regions, which leads
to transcription of genes related to proliferation, immunoregulation, matrix modulation, angiogenesis,
and formation of metastasis. Curcumin inhibits the activation of NFκB by blocking the IKK-complex.
Figure 2. Schematic illustration of the effects of curcumin on prostate cancer. Curcumin has various
effects on the development and progression of cancer via inhibition of NFκB signaling, followed by a
downregulation of its target genes. Curcumin reduces tumor cell proliferation, induces apoptosis (d,e),
and inhibits angiogenesis (c). Additionally, Curcumin inhibits gene expression of matrix-degrading
proteases (matrix metalloproteases) and thereby invasion of tumor cells (a,b). Furthermore, the expression
of metastasis-associated genes is reduced (f). As a summation of the single effects, the inhibition of lung
metastasis in an animal model (murine mouse model) can be considered (g).
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Downregulation of cyclin A, G2/M cell cycle arrest, and upregulation of the CDK inhibitor p21
and Cdc2 have been observed in human colon and bladder cells [31,32]. Moreover, Curcumin treatment
suppressed Bcl-XL, cyclin, and cyclin-dependent kinase (CDK)1 levels, increased cleavage of PARP
(Poly ADP (Adenosine Diphosphate)-Ribose Polymerase), and reduced mitochondrial membrane
potential [33,34]. In a preclinical study with androgen-sensitive LnCaP and androgen-insensitive PC3
prostate carcinoma cells, Curcumin induced cell cycle arrest followed by the induction of apoptosis by
cyclin-dependent kinase inhibitor (CIP) p21(WAF1/CIP1) (WAF1: wild-type p53-activated factor 1) [35].
Curcumin and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L interact
to induce cytotoxicity in the prostate cancer cell line LnCaP [36]. It has been shown in an
animal model that the polyphenol sensitizes even TRAIL-resistant prostate cancer cells to undergo
apoptosis. The respective mechanistic in vitro studies revealed that Curcumin induces expression of
TRAIL-R2/DR5, TRAIL-R1/DR4, Bax, Bak, p21WAF1, and p27KIP1(Cyclin-dependent kinase inhibitor
1B), and inhibits synthesis of NFκB and its gene products, such as Bcl-2 and Bcl-XL, cyclin D1,
vascular endothelial growth factor (VEGF), uPA, MMP-2, MMP-9 [37,38], whereby Bax and Bak
seem to be essential for maximum apoptotic response to Curcumin [39].
The involvement of Curcumin in inhibiting expression of phosphatidylinositol-3 kinase (PI3K)
p110 and p85 subunits, and phosphorylation of Ser 473 Akt/PKB, has been demonstrated by
Shanker and colleagues. In this study, they show that Curcumin upregulates p53 expression and its
phosphorylation at serine 15 in prostate cancer cells. Through the concerted action on all these factors
and the mitochondrial death pathway, Curcumin induces apoptosis [40].
2.2. Curcumin Inhibits MMP Expression and Thereby Tumor Cell Invasion
Proteolytic enzymes such as matrix metalloproteinases (MMPs) are capable of degrading basal
membrane (BM) and extra cellular matrix (ECM) components and are therefore responsible for the
destruction of peritumoral matrix enabling the invasive growth pattern [41]. Thereby, MMPs facilitate
invasion and metastases by promoting migration of tumor cells from the primary tumor site into
the surrounding tissue and secondary distant organ sites by entering the blood stream and the
lymphatic system.
We and others have shown that the expression of MMPs correlates with the growth behavior of
tumor cells in vitro and in vivo [42–45]. MMPs are involved in many biological processes covering
many aspects of tumor progression, such as growth factor activation [46], tumor growth, invasion,
tumor-associated inflammation, angiogenesis, and metastasis [47,48]. The control of MMP expression
and activation is therefore an important target for cancer prevention.
Inhibition of MMP expression starts at the level of gene transcription. The promoter regions of
the genes encoding for MMP-1, -2, -3, -7, -9, -12, and -13 contain a proximal activating-protein-1 (AP-1)
binding site approximately 70 bp 5′ to the transcription start [49,50], and most of them are NFκB-like
elements [51,52].
The effect of Curcumin on MMP expression and activity has been studied extensively
in vitro and in vivo in inflammatory diseases [53,54] and a series of cancer cell lines [16,55–59].
Curcumin suppresses synthesis of many MMPs through downregulation of AP-1 and NFκB [16].
Kim and coworkers demonstrated that Curcumin inhibits 12-O-tetradecanoylphorbol-13-acetate
(TPA)-induced MMP-9 expression and cell invasion by suppressing NFκB and AP-1 activation [60].
Our own studies revealed that Curcumin treatment of breast cancer cells resulted in strongly
diminished levels of MMP-1 and MMP-2 mRNA and protein, while MMP-3 and -9 expression
levels have not been reduced considerably [16]. Similarly, proteolytic activities of the gelatinases
MMP-2 and -9, as evidenced as gelatinolytic activity by zymography, were downregulated upon
Curcumin treatment. Another group showed that all three curcuminoids (demethoxycurcumin,
bisdemethoxycurcumin, and curcumin) significantly inhibited the expressions of MMP-2 and MMP-9,
but not urokinase plasmin activator (uPA) activity and in vitro invasiveness of human fibrosarcoma
cells [61]. Likewise, the plant polyphenol downregulated expression of MMP-2, integrin receptors,
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focal adhesion kinase (FAK), and MT1-MMP to almost background levels in laryngeal squamous
carcinoma cells, leading to significantly reduced invasive potential of the tumor cells. After drug
withdrawal, expression of MMP-2, integrin receptors, MT1-MMP, and FAK, an important component
of the intracellular signaling pathway, returned to control levels [55]. In human colon cancer cells,
Curcumin diminished MMP-2 expression and promoted MMP-9 expression, but did not affect MMP-7,
based on Western blotting assays on protein levels and confirmed by cDNA microarray on the
respective mRNA levels [56]. Curcumin-treated prostate cancer cells (DU-145) had significantly
reduced MMP-2 and MMP-9, along with impaired in vitro cellular invasion. In a corresponding
xenograft model, tumorigenicity was diminished upon Curcumin treatment [57]. The highly metastatic
murine melanoma cells B16F10 exhibited significantly reduced MMP-2 activity after treatment with
Curcumin for 15 days [58]. Expression of MT1-MMP and FAK were also reduced to almost background
levels. MMP-2, MT1-MMP, and FAK did not return to control levels even after 28 days of drug
withdrawal. In the same in vitro model, Curcumin inhibited invasion along with migration and, on the
other hand, enhanced apoptosis [62,63]. Curcumin inhibited the TPA-induced mRNA expression of
MMP-1, -3, -9, and -14 in glioma cells [64] and suppressed various cell survival and cell proliferative
genes, including Bcl-2, cyclin D1, IL-6, COX-2, and MMP-9 on head and neck squamous carcinoma
cells [65]. In a xenograft model of prostatic cancer, Curcumin treatment lead to a significant reduction
of MMP-2 and MMP-9 expression, and the inhibition of the invasive ability of the tumor cells in vitro.
In this study, Curcumin reduced markedly the tumor volume, along with MMP-2 and MMP-9 activity
in the tumor-bearing site, and the number of metastatic nodules in vivo in contrast to the untreated
control group [57]. In the presence of estrogen, Curcumin inhibits expression of estrogen receptor
(ER) in MCF-7 breast cancer cells, along with ER downstream genes, including pS2 and TGFβ. In the
same study, Curcumin downregulated MMP-2 along with upregulation of TIMP-1 (tissue inhibitor of
metalloproteinase) [66].
Anti-invasive effects of Curcumin have been reported also on lung cancer: migration and invasion
of A549 cells were reduced in a time- and concentration-dependent manner by inhibition of MMP-2,
-9, and VEGF [17]. Additionally, these effects could be detected not only in vitro but also in vivo on
801D cells. The underlying molecular mechanism involved the Rac-dependent pathway, which was
inhibited by Curcumin, resulting in a reduction of MMP-2 and -9 [67].
In summary, Curcumin modulates the levels of almost all MMPs, with minor differences in the
efficiency and some variety with respect to the MMPs affected. This may be caused by differences in
responsiveness and partial resistance to Curcumin in some cell types, as we have shown previously
in metastatic melanoma cells [23]. However, through the modulation of MMP/TIMP expression and
activity, Curcumin considerably inhibits degradation of components of the basal membrane and the
extracellular matrix, proving a rationale for reduced tumor invasion and growth.
2.3. Curcumin’s Anti-Inflammatory Action and Its Impact on Tumor Progression
Already in the late 19th century, Rudolf Virchow proposed the contribution of inflammation to
tumor progression, which has been confirmed recently by new evidence [68]. Cancer and inflammation
are connected by the intrinsic (activated oncogenes) and extrinsic (inflammation, infections) pathways
leading to the activation of the three transcription factors: NFκB, STAT3 (signal transducers and
activators of transcription 3), and HIF1α (hypoxia-induced factor 1α) [69]. There is substantial
evidence that Curcumin modulates NFκB [70,71], and that most of the anti-inflammatory activities
of the polyphenol can be attributed to the inhibition of the IκB kinase, IKK. Upon phosphorylation
by IKK, IκB translocates into the proteasome, where it becomes degraded. In the absence of IκB,
the NFκB subunit p65 becomes phosphorylated and translocates into the nucleus, where it can activate
transcription of a large number of inflammation- and survival-related genes. It has been described that
Curcumin inhibits STAT3 [72,73] and HIF1α directly, as well as indirectly through aryl hydrocarbon
receptor nuclear translocator [74,75]. We have published previously that IL6—a downstream target of
STAT3—is regulated by Curcumin [15].
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Through reducing the activity of the transcription factors NFκB and STAT3, Curcumin determines
a diminished expression of inflammatory cytokines [14,15], which in turn could decrease the attraction
of inflammatory cells to the tumor site.
NFκB, TNFα, and its downstream target COX2 are known to be key players in inflammation,
and, at the same time, they promote tumor growth and metastasis by triggering proliferation and
angiogenesis and impede apoptosis [76]. We and others have found that Curcumin inhibits NFκB
expression and activity, and decreases COX2 levels, both key events in inflammation, as well as
cancer progression [15,16,31,70,77]. Inhibition of NFκB occurs through modulation of the IκBα
pathway, which is directly targeted by Curcumin [78]. Through the suppression of NFκB, a variety
of inflammatory cytokines, which have been shown to mediate tumorigenesis, are modulated by
Curcumin. In addition, the natural polyphenol inhibits the expression of a series of interleukins (IL-1, -2,
-5, -8, -12, -18) [79–83], which are significantly involved in the induction of MMPs, adhesion molecules,
and signaling pathways related to invasion and an-giogenesis, like NFκB, TNF, and STATs.
By gene silencing of the NFκB subunit p65, we found that inhibition of CXCL-1 and -2 expression
(CXCL-1: chemokine C-X-C motif ligand 1) by Curcumin in breast cancer cells is mediated through
NFκB [15]. Furthermore, we showed that this mechanism requires intact IκBα expression upstream of
NFκB. Well in line, we found that Curcumin inhibits translocation of NFκB to the nucleus through
the inhibition of the IκB-kinase (IKKβ), leading to stabilization of the inhibitor of NFκB, IκBα, in PC-3
prostate carcinoma cells. Thereby, p65 is not translocated into the nucleus, whereby expression of
CXCL-1 and 2 and the autocrine/paracrine loop that links the two chemokines to NFκB are abolished.
The combined application of Curcumin with the synthetic IKKβ inhibitor SC-541 in prostate cancer
cells did not show any additive or synergistic effects, indicating that the two compounds share the
target (Figure 3) [14].
Figure 3. Feedback loop of CXCL-1 and 2 and NFκB. The proinflammatory chemokines CXCL-1 and -2
activate NFκB (b) by binding to their receptor CXCR-2 (a). In consequence, NFκB translocates into the
nucleus and starts transcription of CXCL-1 and 2 (c). The chemokines are secreted and bind again to
CXCR-2, activating NFκB (d). Curcumin disrupts this feedback loop by inhibition of NFκB (e).
Inactivation of NFκB—which occurs in the tumor cell, as well as in the inflammatory cell—might
be the reason why Curcumin, which is known to have only modest pharmacological effects,
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has these relatively strong chemopreventive properties, most likely synergistically interrupting the
cross-stimulatory effect of cytokine production.
Interestingly, the downregulation of the cytokine CXCL-1 leads to reduced expression of CXCR-4,
the receptor for CXCL-12/SDF1 [15], addressing a metastasis-promoting axis that has been recognized
as a target for drug development [84].
Although CXCL-1 is expressed by only very few breast cancers [85], it is present in the lung
metastasis signature [86]. Thereby, the cytokine might be a suitable response marker for secondary
prevention by Curcumin in other cancer types that frequently overexpress CXCL-1.
2.4. Curcumin Modulates MicroRNA Expression
In ambition to identify novel target pathways to describe the antitumorigenic properties of
Curcumin, the system of microRNAs cannot be neglected. MicroRNAs (miRNA or miR) are highly
conserved, noncoding RNAs composed of 20–22 nucleotides, which are encoded in the genome of
plants, animals, and humans.
It has been speculated that miRNAs serve as rivals to the commonly known system of transcription
factors in eukaryotic cells, regulating the expression of about 60% of mammalian genes [87–89].
miRNAs are involved in numerous processes of development, differentiation, proliferation, and apoptosis,
to mention only a few. Their involvement in several human diseases—in particular cancer [90,91],
with some miRNAs being up- and others downregulated—has been described in literature [92–94].
They can regulate protein expression post-transcriptionally by controlling the expression of several
proteins through binding to the 3′ UTR of the respective mRNA, thus resulting in mRNA degradation or
inhibition of mRNA translation [95]. miRNAs can act as either tumor promoters (“oncomiRs”–miRNAs
that act as oncogenes) or tumor suppressors (tumor suppressor miRs) [90,91,96]. In this context,
miRNAs can modulate every single step of tumor progression, from proliferation and tumor cell
growth to migration and invasion, and several miRNAs have even been associated to metastasis
(“metastamirs”) with both prometastatic and antimetastatic effects [97,98].
One of the first preclinical studies to test the effect of Curcumin on miRNA expression has
been performed by Sun and coworkers. In a microchip test for the most important—and potentially
relevant—miRNAs, they found that Curcumin upregulated miRNA-22 and downregulated miRNA-199a
in human pancreatic cancer cells (cell line PxBC-3) [99]. Accordingly, they suggested that Curcumin
interferes with the miRNA system in human cancer cells, providing an additional anticancer effect
yet to be explored in depth. In our own studies on metastatic breast cancer cells, we showed that
Curcumin modulates the expression of miR181b, along with a series of other miRNAs. Investigating
the consequences of miR181b modulation on tumor progression and metastases, we found that
miR181b downmodulates CXCL-1 and -2 through a direct binding to their 3′-UTR. We could prove
a direct correlation between the cytokines and miR181b by overexpression or inhibition of miR181b
in metastatic breast cancer cells, which had a significant impact on CXCL-1 and -2 expressions and
subsequently on metastasis formation in vivo in immunodeficient mice [21].
It has been shown that antiproliferative and proapoptotic effects of Curcumin are in part mediated
by miRNAs. By upregulating miR192-5p, Curcumin suppresses the P13K/Akt signaling pathway
and thereby inhibits proliferation and induces apoptosis in NSCLC cells [100]. Well in line, the tumor
suppressor PTEN, a negative regulator of P13K/Akt, can be induced by Curcumin through suppressing
miR-21 [101]. Other signaling pathways and factors that control proliferation and apoptosis comprise
caspase-10, which is under the control of miR-186. By upregulating this miRNA, Curcumin inhibits
progression of lung adenocarcinoma [102]. Downregulation of WT1 (Wilms tumor 1) by Curcumin
through upregulation of miR-15a and miR-16-1 reduces proliferation in leukemic cells [103].
Besides acting on the P13K/Akt pathway and thereby on proliferation and apoptosis,
Curcumin modulates also cell cycle arrest by promoting p21 via inhibition of miR-208 in prostate
cancer cells [104]. Other miRNAs that are modulated by Curcumin and have impact on cell cycle,
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in particular on G2/M phase arrest, are miR21, an oncomiR, significantly increasing the number of
viable cells, and miR-34a, which are both decreased by Curcumin [105,106].
As miRNAs are known to regulate invasion and metastases formation and Curcumin is known to
inhibit these processes, it is more than likely that the anti-invasive and antimetastatic effects of the
polyphenol are at least in part mediated by miRNAs.
In our own studies, we have demonstrated that miR181b inhibits expression of the matrix-degrading
enzymes MMPs (matrix metalloproteinases), leading to reduced tumor cell invasion. We found that
miR181b overexpression in metastatic breast cancer cells downregulates expression of genes belonging
to the breast cancer lung metastases signature [86], and that miR181b overexpression in breast cancer
cells inhibits metastases formation in vivo [21]. Similar findings were made on nasopharyngeal
carcinoma (NPC), where Curcumin reduced formation of metastases by downregulating the expression
of miR-125a-5p [107]. Interestingly, Curcumin analogs also have been found to inhibit invasion and
metastases through miRNAs [108,109].
Altogether, these findings demonstrate that the antitumorigenic activity of Curcumin is mediated
at least to some extent by miRNAs, which regulate a series of complex tumor progression-associated
signaling pathways, like Akt, PTEN, Bcl-2, p53, Notch, and Erbb. Through a clear understanding of the
relation between Curcumin and miRNAs, we can improve therapeutic strategies and find biomarkers
for their efficacy. Thereby, the use of Curcumin will enrich the possibilities for more efficient and less
toxic cancer therapies.
3. Metastatic Setting—A Possible Preventive Approach by Curcumin
In the last 15 years since Douglas Hanahan and Robert Weinberg described, for the first
time, the hallmarks of cancer [110], various aspects of the metastatic program have been elucidated,
particularly for carcinomas, which account for about 80% of cancer cases and the majority of cancer deaths.
Cancer research can be regarded as an increasingly logical science, in which many phenotypic complexities
result from a small set of underlying organizing principles [111]. Nevertheless, metastatic growth is still
regarded as a multistep process, beginning with dissemination of carcinoma cells from the primary
tumor site and ending with the arrival and growth in a distant tissue or organ.
Motility, degradation of basement membrane and extracellular matrix components, and invading
into blood or lymphatic vessels are prerequisites for a tumor cell to metastasize.
During this process, many steps occur, like degradation processes, invasion, interactions with
other cells, and many more.
Data from various tumor models underline the antimetastatic effect of Curcumin. First experiments
using Curcumin as an antimetastatic agent were made by Menon and coworkers in 1995 [112], who tested
in an in vivo model to see if Curcumin was able to inhibit the formation of lung metastases by
B16F10 melanoma cells. In this study, Curcumin, orally administered in combination with catechin
at “physiological” concentrations, was found to inhibit the formation of lung metastases by 80%
and to increase the lifespan of animals by approximately 150%. In addition, Curcumin proved to be
the strongest drug out of a dozen substances. In an orthotopic mouse model, implanted metastatic
Lewis lung carcinoma (LLC-MLN) cells, selected in vivo, resulted in greater metastatic growth in
mediastinal lymph nodes as compared to the original population [113]. By oral administration of
Curcumin, mediastinal lymph node metastasis of implanted LLC cells was significantly inhibited
without affecting the tumor growth at the implantation site. Even better results were obtained when
Curcumin was administered in combination with the anticancer drug cis-diamine-dichloroplatinum
(CDDP), which markedly inhibited tumor growth at the implanted site and lymphatic metastasis,
and significantly prolonged survival.
The effect of Curcumin on DNA damage and lipid peroxidation was tested in vivo in a rat model
of liver tumor resulting from copper-induced oxidative stress [114]. In this study, Curcumin suppressed
formation of metastases, although it did not influence the tumor incidence of the primary liver tumors.
Similarly, upon Curcumin treatment, significantly fewer metastases in a tumor model of prostatic
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carcinoma cells (DU-145) injected into immunodeficient mice [57] were observed, and in paclitaxel
(Taxol)-resistant breast cancer cells a significant reduction in the incidence of breast cancer metastasis
was reported.
Our own studies [14–16,21] revealed that formation of breast and prostate cancer metastasis
in vivo was significantly reduced (Mann Whitney p < 0.01) in immunodeficient mice 5 weeks after
injection. Surprisingly, four Curcumin-treated and none of the control animals in the breast cancer
model remained metastases free.
In order to investigate the underlying molecular mechanisms, we analyzed all genes differentially
expressed between Curcumin-treated and untreated MDA-MB-231 breast cancer cells. Our own
microarray mRNA expression experiments resulted in 62 genes that were statistically significantly
regulated by Curcumin, with the two proinflammatory cytokines, CXCL-1 and -2, among the
strongest downregulated genes [15]. Both play a significant role in migration, growth, metastasis,
and angiogenesis of tumor cells of different organs [115,116]. Our results were well in line with those
previously published showing highly metastatic subclones derived from MDA-MB-231 cells by dilution
cloning overexpress CXCL-1 and -2. However, the question of whether expression of these chemokines
is causally linked to invasion and metastasis remained open [86]. Therefore, we validated our previous
findings in a model of metastatic prostate cancer and investigated whether CXCL-1 and -2 are causally
correlated with formation of metastases. Treatment of the cells with Curcumin and siRNA-based
knockdown of CXCL-1 and -2 induced apoptosis, inhibited proliferation, and downregulated several
important metastasis-promoting factors, like COX2, secreted protein acidic and rich in cysteine
(SPARC), and EGF-containing fibulin-like extracellular matrix protein (EFEMP). In an orthotopic
mouse model of hematogenous metastasis, treatment with Curcumin statistically significantly inhibited
formation of lung metastases. Including the involvement of small noncoding RNAs (miRNAs) in tumor
progression in our further studies concerning the molecular mechanisms of metastases formation and
prevention by Curcumin, we demonstrated that the natural polyphenol modulates the expression
of miR181b, along with a series of other miRNAs in metastatic breast cancer cells. Investigating the
consequences of miR181b modulation on tumor progression and metastases, we found that miR181b
downmodulates CXCL-1 and -2 through a direct binding to their 3′-UTR. We could prove a direct
correlation between the cytokines and miR181b by overexpression or inhibition of miR181b in
metastatic breast cancer cells, which had a significant impact on CXCL-1 and -2 expressions and
subsequently on metastasis formation in vivo in immunodeficient mice [21].
We have developed the following model for the chemopreventive effect of Curcumin against
formation of metastases (Figures 1 and 2) based of our own results. By targeting its upstream inhibitor,
IκBα, Curcumin acts on the tumor progression- and inflammation-related NFκB pathway. Inhibition of
the transcription factor NFκB—along with other transcription factors, e.g., AP-1—leads to diminished
expression of matrix-degrading proteases, like MMPs, and in consequence to reduced invasive
capacity of the tumor cells. Additionally, Curcumin induces apoptosis by reducing the expression
of NFκB-dependent survival factors. Through NFκB, Curcumin also impairs the synthesis of the
proinflammatory cytokines CXCL-1 and -2, and, downstream that, of a series of metastasis-related
genes. The concerted action of all these molecular processes leads to diminished formation of
metastases in vivo.
4. Perspective
Curcumin has been used as dietary spice for centuries, even for more than 5000 years, in ayurvedic
medicine and traditional Chinese medicine to treat inflammatory diseases. Its potential in cancer
prevention and therapy is supported by numerous preclinical studies, and even in some clinical studies
or healing attempts. However, there are few studies that clearly indicate adverse effects in cancer
treatment. Therefore, future studies should be directed not only towards efficacy but also towards
safety of Curcumin in preventing tumor progression and metastases formation.
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As the prevention triad comprises not only primary prevention—thus intervention/action before
the onset of cancer—but also secondary and tertiary prevention, we should start to pave the way for
the application of Curcumin in the clinical setting.
At present, the major obstacles of using Curcumin in cancer prevention and treatment trials
are its low bioavailability due to its hydrophobic character and its rapid metabolic rate [117].
Although new derivates and nanoparticles of Curcumin—like liposomes, polymeric micelles,
and nanoparticles—have been designed in the last decade, the use is still restricted due to sometimes
severe side effects of these new formulations.
Curcumin has demonstrated considerable antitumor effects in various tumor cell models. There is
remarkable concordance between preclinical in vitro/in vivo studies and first clinical phase II trials
in end-stage cancer patients, and it appears that Curcumin indeed exerts, at least in some tumors,
clinically relevant anticancer effects. With ongoing research in the future, the list of tumor types that
respond to Curcumin is likely to grow further.
Our own results reveal that Curcumin acts on apoptosis, expression of matrix-degrading enzymes,
invasion, and expression of inflammation-related genes. The concerted action of a variety of molecular
processes converges into diminished formation of breast and prostate cancer metastasis, as we have
shown for the first time in a mouse model of hematogenous metastasis.
Formation of metastasis and metastatic lesions is the final step of a largely incurable illness,
and the possibility to prevent this situation is at present the only chance for patients to prolong lifespan
and quality of life. At present, we understand metastatic disease as a multistep process predominantly
driven by dissemination, invasion, and colonialization.
The ideal chemopreventive agent against metastatic disease should therefore act against these
three processes and not exert adverse effects. This review has extensively shown that Curcumin is
effective against invasion and growth of tumor cells. Thereby, Curcumin has the potential to modulate
the processes of invasion and colonialization. Dissemination of carcinoma cells is strongly influenced
by interactions during transit through the circulating system. In this context, the escape from the
arms of the immune system is essential for the tumor cell to be able to settle at a distant location
for colonialization. Curcumin has been shown to exert immunomodulatory effects on several cells
and organs of the immune system and is therefore recognized as a potent modulator of the immune
system [118]. Additionally, we have summarized in this review irrevocable evidence that Curcumin is
a potent inhibitor of metastases formation.
Due to the overwhelming evidence from preclinical studies, we think that the next step is to
test Curcumin in clinical trials in order to prove its antitumor activities. However, some aspects
have to be considered to elevate the success rate or to prevent failure, like in the case of the SELECT
(selenium and Vitamin E cancer prevention trial) study, where vitamin E and selenium were tested as
chemopreventive agents against prostate cancer [119–121]. With all the knowledge we have gained
from preclinical studies on the molecular mechanisms of Curcumin’s antitumor activities, trials should
be limited to cancer types with a documented role of NFκB and inflammation in tumor progression.
In order to translate the preclinical finding to clinical evidence, the primary cancer should be available
for molecular analysis and expression studies. In order to gain better insight into the bioavailability,
Curcumin and its metabolites should be monitored in human specimens. Finally, patients should
be stratified based on molecular and biochemical data in order to detect significant responses in
subgroups of patients.
The still incompletely resolved issue of bioavailability should be addressed in future preclinical
and clinical studies, since we need to attribute Curcumin’s antitumor activities to specific molecules
circulating in the blood or present in the target organs. Another issue that has to be addressed in future
studies is resistance against Curcumin, which can be expected more frequently when administered to
patients for longer time periods, including innate resistance in some tumors that are known as difficult
to treat, such as melanoma, as we have published previously [23].
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Attention should also be paid to combinations of Curcumin with chemotherapy [122,123] or with
other plant-derived bioactive substances with preclinically proven antitumor activities. In this context,
clinical studies should be carried out to collect scientific evidence for clinical application also with
respect to Curcumin’s protective features against undesired side effects [124–128] or its reinforcing
power in combination with classic antineoplastic therapies [129].
Besides still missing evidence from large clinical trials, Curcumin, like other natural plant-derived
bioactive compounds, has further two major disadvantages that render it commercially unattractive:
it is too cheap and nonpatentable. However, the comprehensive data from preclinical studies,
together with first clinical results from single patients or small cohorts, makes it very likely that
Curcumin can contribute significantly to the improvement of cancer therapy and prevention.
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